Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lanthanum polystyrene sulfonate is a **small molecule drug** under development as a **phosphate binder** for the treatment of **hyperphosphatemia** primarily in patients with end-stage renal disease undergoing hemodialysis. It acts via cation exchange, binding phosphate ions in the gastrointestinal tract to reduce serum phosphate levels. Its mechanism is distinct from classic potassium binders, utilizing the lanthanum ion integrated into polystyrene sulfonate resin. The drug is not absorbed systemically and exerts its effect via sequestration and removal of phosphate ions through fecal excretion. Clinical data includes phase 1/2 studies in patients with end-stage renal disease and hyperphosphatemia[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lanthanum polystyrene sulfonate.